25.04.2012 - Even after the takeover of German-American Micromet Inc. by Amgen, Bite antibody technology remains interesting for other pharma partners.
Berlin/Martinsried – Bayer HealthCare has agreed to extend its collaboration with Amgen Research GmbH, as the former Micromet site in Munich is called today. Bayer and its partner will develop another new Bispecific T cell Engager antibody against an undisclosed target expressed in multiple tumours. The German pharma had forged a first option, collaboration and license agreement with Micromet in January 2009 to discover and develop a novel BiTE antibody targeting PSMA (prostate specific membrane antigen) for the treatment of patients with prostate cancer. Amgen acquired Micromet in March this year for US-$1.2bn and promised to keep the German site as its largest research centre outside the US. Under the terms of the present agreement, Bayer will collaborate with Amgen Research from the research phase through to the completion of Phase I clinical trials, upon which Bayer will assume full control of further development and commercialisation of the product candidate. The cooperation also includes evaluation of BiTE antibodies with an extended serum half-life. Financial details of the collaboration were not disclosed. Meanwhile, the development of the initial BiTE antibody resulting from the 2009 collaboration progresses according to plan and the initiation of the clinical Phase I trial could start as early as in the second half of 2012.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
JANUS® G3 Automation Workstations deliver real-time and future adaptability in throughput, capacity, and dynamic volume range from 0.5 μl to 5000 μl for consistent and reproducible sample preparation more